Professor Liu Jianmin's team from Changhai Hospital completed the first clinical trial of the “Tongqiao Kirin” blood flow guide device

On the morning of July 7, 2021, Professor Liu Jianmin's team from the Cerebrovascular Disease Center of Shanghai Changhai Hospital completed the “Tongqiao Kirin” blood flow guide device (single arm) clinical trial projectFirst patient enrolledProfessor Hong Bo completed the stent implantation at a high level. This study is another study by Tsuqiao focusing on the efficacy and safety of endovascular treatment of small unruptured aneurysms following a study on the efficacy and safety of the “Tsuhashi Kirin” blood flow guide device for endovascular treatment of large intracranial unruptured aneurysms. The study not only expanded the range of indications for the “Tsuqiao Kirin” blood flow guide device, but also potentially accelerated the marketing process of the Tsuqiao blood flow guide device product.

The blood flow guide device is one of the key innovations in Tongqiao Neurovascular Interventions's comprehensive product portfolio for intracranial aneurysms. The “Tsuqiao Kirin” blood flow guide device is highly innovative. The product design uses full-body imaging. It has characteristics such as remote stent closure, speaker design, moderate radial force, and strong wall adhesion, which fully reflects the comprehensive level of medical device development. The clinical trial was led by Shanghai Changhai Hospital, and dozens of clinical research institutes from all over the country, including Huashan Hospital affiliated to Fudan University, participated.

Professor Hong Bo of Changhai Hospital completed the enrollment of the first patient. The enlisted patient's internal carotid artery was curved, and the aneurysm was located in the ocular artery section. This operation was quite challenging. After surgery, Professor Hong Bo was very satisfied with the product. He said, “The 'Tongqiao Kirin' blood flow guide device performed well, the pumping process was very smooth, the adhesion determination was good after release, the contrast was obvious, the aneurysm contrast agent stayed, the tumor-carrying artery was unobstructed, and the operation went smoothly. I hope the patient has a good prognosis and a speedy recovery.”

Currently, domestic neurovascular intervention products are still in the early stages of development. Achieving “domestic production instead of import” through innovative research and development is the common vision of domestic medical device companies. With more and more experience in clinical practice, blood flow guidance devices are gradually becoming one of the important methods for treating various types of intracranial aneurysms. With the continuous improvement of technical standards, I believe that in the near future, domestic neurovascular intervention products such as “Tsuhashi Kirin” can provide doctors in this field with higher quality and more diverse surgical options, as well as more individualized and safe treatment plans for patients.


The copyright of this article/picture/video belongs to Chuangtongqiao Medical Technology Co., Ltd. It is an original professional material for medical reference only. Unauthorized reprinting, copying or dissemination is prohibited.